INDRAPRASTHA MEDICAL share price has plunged 5% and is presently trading at Rs 447.2.
Meanwhile, the BSE HEALTHCARE index is at 43,497.7 (up 0.1%).
Among the top losers in the BSE HEALTHCARE index today are Glenmark Pharma (down 2.5%) and SUVEN PHARMACEUTICALS (down 2.2%).
ASTRAZENECA PHARMA (up 4.0%) and ERIS LIFESCIENCES (up 3.5%) are among the top gainers today.
Over the last one year, INDRAPRASTHA MEDICAL has moved up from Rs 197.9 to Rs 447.2, registering a gain of Rs 249.3 (up 126.0%).
On the other hand, the BSE HEALTHCARE index has moved up from 28,646.0 to 43,497.7, registering a gain of 51.8% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 205.7%), SUVEN PHARMACEUTICALS (up 114.1%) and Glenmark Pharma (up 102.9%).
For Investors: Our Big Prediction
The BSE Sensex is at 78,854.1 (down 0.8%).
The top losers among the BSE Sensex today are HDFC Bank (down 2.6%) and Asian Paints (down 2.6%). The most traded stocks in the BSE Sensex are Tata Motors and Tata Steel.
In the meantime, NSE Nifty is at 23,947.3 (down 0.8%). HDFC Bank and Asian Paints are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 64,975.6 to 78,854.1, registering a gain of 13,878.5 points (up 21.4%).
INDRAPRASTHA MEDICAL net profit grew 29.1% YoY to Rs 424 million for the quarter ended September 2024, compared to a profit of Rs 329 million a year ago. Net sales rose 10.4% to Rs 3,498 million during the period as against Rs 3,170 million in July-September 2023.
For the year ended March 2024, INDRAPRASTHA MEDICAL reported 43.9% increase in net profit to Rs 1,240 million compared to net profit of Rs 862 million during FY23. Revenue of the company grew 13.3% to Rs 12,447 million during FY24.
The current Price to earnings ratio of INDRAPRASTHA MEDICAL, based on rolling 12 month earnings, stands at 27.7.
Equitymaster requests your view! Post a comment on "INDRAPRASTHA MEDICAL Plunges 5%; BSE HEALTHCARE Index Up 0.1%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!